系统综述与《抗微生物化疗杂志》:过去、现在与未来的系统性再评价
自2003年以来,《抗微生物化疗杂志》已发表超过200篇系统综述,许多被广泛引用。本文以13篇ICU肺炎预防系统综述为案例,说明系统综述方法与纳入原始研究的假设和局限性如何影响推论,并指出数据来源是新出现的威胁。系统综述需适应新挑战并验证关键假设,尤其针对抗菌药物感染预防干预的溢出效应。
要点
- 系统综述的推论受其方法与原始研究假设的显著影响。
- 以13篇ICU肺炎预防系统综述为例,抗菌干预对个体ICU患者与ICU人群的推论可不同。
- 系统综述需适应数据来源等新威胁,并验证关键假设以保持相关性。
核心结论
- 系统综述需适应新出现的挑战,并识别和验证关键底层假设,才能继续服务于循证医学。
研究设计与样本
- 本文为对《抗微生物化疗杂志》已发表系统综述的回顾性再评价,并以13篇ICU患者肺炎预防系统综述为案例研究。
主要发现
- 自2003年以来该杂志已发表超过200篇系统综述,许多被广泛引用。
- 案例研究显示,依据不同假设,抗菌药物干预的系统综述可在对个体ICU患者预防肺炎与对ICU人群造成伤害两种推论间摆动。
- 数据来源是系统综述新出现的威胁,系统综述方法与纳入原始研究均存在多种假设和局限性。
临床怎么用
- 临床解读系统综述时需关注其底层假设与原始研究局限性,而非仅看汇总效应量。
- 针对抗菌药物感染预防干预的系统综述,应考虑其潜在溢出效应。
局限性
- 本文为对已发表系统综述的再评价,未报告新的原始研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since 2003, >200 systematic reviews (SRs) have been published in the Journal of Antimicrobial Chemotherapy (JAC). Many have been widely cited. Guidelines for proper execution were outlined in 2005. Since then, new threats, challenges and methods have emerged. Data provenance is an emerging threat. There are several assumptions and limitations of both SR methods and the primary studies they include. The pivotal impact of these assumptions is illustrated using 13 SRs of pneumonia prevention in ICU patients on inferences towards the aspirational goal of 'Pneumonia zero' as a case study. Depending on these assumptions, the SRs of antimicrobial-based interventions pivot between two not incompatible inferences of pneumonia prevention for individual ICU patients versus harm for ICU populations. The case study highlights how newer methods for data visualization enhance reader insight into the underlying data beyond the summary effect size. To remain relevant to evidence-based medicine, SRs will need to adapt to emerging challenges and to recognize and validate the key underlying assumptions. This is especially so for antimicrobial-based infection prevention interventions given their potential for spillover effects.
引用
- Hurley JC. Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal. J Antimicrob Chemother. 2025. PMID: 40836863. doi:10.1093/jac/dkaf282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。